NCT00354029

Brief Summary

The purpose of this study is to determine whether the use of perioperative intravenous S (+) ketamine reduces the amount and degree of postoperative pain. Furthermore the purpose of this study is to determine whether the use of perioperative intravenous S (+) ketamine effects cognitive function in the early postoperative period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
83

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Aug 2006

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 18, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 19, 2006

Completed
13 days until next milestone

Study Start

First participant enrolled

August 1, 2006

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
2.2 years until next milestone

Results Posted

Study results publicly available

July 20, 2011

Completed
Last Updated

July 20, 2011

Status Verified

July 1, 2011

Enrollment Period

1.8 years

First QC Date

July 18, 2006

Results QC Date

May 24, 2011

Last Update Submit

July 19, 2011

Conditions

Keywords

hemorrhoidshemorrhoidectomyS (+) ketaminepain

Outcome Measures

Primary Outcomes (1)

  • NRS Pain = Numeric Rating Scale (0-10)

    The numeric rating scale (NRS) is used to measure the intensity of pain. The value 0 means no pain and the value 10 represents maximal pain. a higher intensity of pain is associated with a worse outcome.

    24 hours

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Saline 0,9%

Drug: Placebo

S (+) Ketamine

ACTIVE COMPARATOR
Drug: S (+) Ketamine

Interventions

0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery

S (+) Ketamine

isotonic saline

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of disc prolapse
  • Age 18+
  • ASA (American Society in Anesthesiology) I-II
  • written consent

You may not qualify if:

  • Age \< 18
  • ASA \> II
  • liver failure
  • renal failure
  • heart failure
  • glaucoma
  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asker and Baerum Hospital

Rud, N-1309, Norway

Location

Related Publications (3)

  • Arendt-Nielsen L, Nielsen J, Petersen-Felix S, Schnider TW, Zbinden AM. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br J Anaesth. 1996 Nov;77(5):625-31. doi: 10.1093/bja/77.5.625.

    PMID: 8957979BACKGROUND
  • Himmelseher S, Durieux ME. Ketamine for perioperative pain management. Anesthesiology. 2005 Jan;102(1):211-20. doi: 10.1097/00000542-200501000-00030. No abstract available.

    PMID: 15618805BACKGROUND
  • Bell RF, Dahl JB, Moore RA, Kalso E. Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand. 2005 Nov;49(10):1405-28. doi: 10.1111/j.1399-6576.2005.00814.x.

    PMID: 16223384BACKGROUND

MeSH Terms

Conditions

HemorrhoidsPain

Interventions

Ketamine

Condition Hierarchy (Ancestors)

Rectal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesVascular DiseasesCardiovascular DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Results Point of Contact

Title
Ulrich J Spreng
Organization
Baerum Hospital

Study Officials

  • Ulrich J Spreng, Dr. med,

    Asker and Baerum Hospital, Norway

    PRINCIPAL INVESTIGATOR
  • Vegard Dahl, Dr. med.

    Asker and Baerum Hospital, Norway

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 18, 2006

First Posted

July 19, 2006

Study Start

August 1, 2006

Primary Completion

June 1, 2008

Study Completion

May 1, 2009

Last Updated

July 20, 2011

Results First Posted

July 20, 2011

Record last verified: 2011-07

Locations